New scanner aims to sharpen cancer radiation accuracy
NCT ID NCT05524454
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new cone-beam CT scanner designed to take clearer images while patients are on the radiotherapy couch. 41 adults with head-and-neck, lung, breast, abdominal, or pelvic cancer each had one or two scans with the new device. The goal was to see if the images were good enough to help guide radiation more precisely, potentially reducing damage to healthy tissue.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Novel cone-beam CT imaging device
- What this could lead to
- If successful, this scanner could provide clearer images during radiotherapy, potentially making cancer treatments more precise and reducing side effects.
- What could go wrong
- This was a small feasibility study with only 41 participants, so results may not apply to all patients or cancer types. The device is not yet proven to improve treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
41 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Aug 2023
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The patient will be treated with external beam photon radiotherapy at Maastro for head-and-neck cancer, stage I lung cancer, stage II-IV lung cancer, left breast cancer, or tumours in the abdominal or pelvic region. * Age ≥ 18 years * Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician * Provision of written informed consent Exclusion Criteria: * Patient is pregnant
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Abdominal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Maastricht Radiation Oncology
Maastricht, Limburg, 6229 ET 12, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- Can a dental assistant keep cancer Patients' mouths healthier during radiation?
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?